Medicamen Biotech reported FY26 turnover of ~178.85 Cr & PAT of ~9.41 Cr, with 80% sales from global markets.

The company boosted R&D/Capex for sustainability and increased MSME sourcing.

A `7,080 fine for a minor filing delay was noted and resolved.

Loans to related parties significantly increased.